Background {#Sec1}
==========

Chronic total occlusions (CTO) are present in about 20% of patients with coronary artery disease undergoing elective angiography \[[@CR1]\]. Nevertheless, these lesions represent only a minority of the lesions treated with percutaneous coronary intervention (PCI), even if their treatment is associated with better outcome in terms of angina relief, improved left ventricular function, reduction in the rate of myocardial infarction and coronary artery bypass grafting (CABG), and potentially prolonged survival, particularly in the setting of multivessel disease when complete revascularization is achieved \[[@CR2]\].

After successful recanalization of the vessel, stenting is mandatory, preferably with drug-eluting stents (DES), to ensure long-term vessel patency \[[@CR3]\]. Although favorable long-term outcome data have been reported after the implantation of DES, the implantation of multiple metallic stents into coronary arteries may lead to an augmented risk of restenosis and thrombosis, impairment of vasomotion and positive remodeling and excludes the possibility of future bypass graft anastomosis within these segments \[[@CR4]\]. In this setting, bioresorbable scaffolds (BRS) might therefore have potential advantages: avoidance of long coronary segments covered with metallic prostheses, restoration of endothelial function and normal vasomotor tone at least within noncalcified segments, long-term favourable vessel remodeling; finally, struts resorption preserves the possibility of further interventions by percutaneous or surgical means \[[@CR5]\].

Conversely, there are also many limitations of BRS use in this subset of lesions: severely calcified vessels may be poorly accessible for bulky devices, and their low radial strength bear the risk of vessel recoil and underestimation of vessel size raise the risk of malapposition.

Importantly, CTO lesions were excluded in all BRS randomized controlled trials published to date \[[@CR6]--[@CR9]\], and all available evidence derives from small single-center, single-arm studies. We therefore undertook a systematic literature review and meta-analysis of studies examining the clinical outcomes of patients with chronic coronary occlusion undergoing BRS implantation.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Electronic searches were performed using Pubmed, Scholar, and Scopus electronic database up to June 13th, 2017. We checked the reference lists from all eligible studies to identify additional citations. The following keywords and the corresponding MeSH terms were used for search: "bioresorbable vascular scaffold", "chronic total occlusion", "coronary artery disease". Time of publication was not limiting criterium for our analysis. All reports including the search terms were independently screened by two investigators for relevance and eligibility (AP, SDR) and any disagreement was resolved by consensus. The study protocol was registered in PROSPERO (CRD42017069322).

Study selection {#Sec4}
---------------

*Inclusion criteria*: 1) patients with at least one coronary chronic total occlusion 2) reports of a minimum of 9 patients with a follow-up at least of 1 month; 3) original articles reporting at least one of these outcomes: target lesion revascularization (TLR), target vessel revascularization (TVR), scaffold thrombosis (ScT), scaffold restenosis (ScR), cardiac death and 4) reports written in English language.

*Exclusion criteria*: 1) duplicate publication 2) pre-specified endpoint 3) measure not specified. If duplicate studies were identified, only the most exhaustive and recent reports were retained.

Data extraction {#Sec5}
---------------

Baseline characteristics as well as numbers of events were extracted from the single studies, through scanning of the full article by two independent reviewers (AP, SDR). Divergences were resolved by consensus.

The following data were abstracted: year of publication, location, number of study patients, study design, clinical outcome data, baseline patients' characteristics, and procedural characteristics.

Study endpoints {#Sec6}
---------------

TLR was the primary outcome of interest. Secondary outcomes were TVR, ScT, clinical ScR, cardiac death.

Statistical analysis {#Sec7}
--------------------

Categorical variables are reported as numbers and percentage, and continuous variables are reported as mean ± SD or median ± IQR. Random effects meta-analysis was conducted in all analyses using the Metaprop command, which allows computation of 95% confidence intervals (CIs) using the score statistic and the exact binomial method and incorporates the Freeman-Tukey double arcsine transformation of proportions \[[@CR10]\]. Heterogeneity among studies was assessed with the I^2^ statistic. The effect of study-level covariates on the rate of TLR, ScT and ScR was explored with a meta-regression analysis by using the metareg command (Additional file [1](#MOESM1){ref-type="media"}). All analyses were performed with OpenMetaAnalyst software version 0.15 \[[@CR11]\] and Stata statistical software version 13 (StataCorp LP, College Station, Texas).

Results {#Sec8}
=======

Search results {#Sec9}
--------------

Our search retrieved a total of 304 entries, which were reduced to 59 studies after an initial pre-screening. 43 studies were then excluded for one of the following reasons: a) they were not related to our research question b) they weren't original articles. In the assessment of eligibility 1 additional study was excluded because as it is limited to in-hospital outcomes \[[@CR12]\]. Finally, a total of 13 studies \[[@CR13]--[@CR25]\] with a median follow-up of 12 months (IQR 6--12) were available for the analysis including 843 lesions. The study selection procedure is reported in detail in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study selection flow chart

Study characteristics {#Sec10}
---------------------

Table [1](#Tab1){ref-type="table"} summarizes the patients´ most relevant baseline characteristics for each study.Table 1Baseline patient's characteristicsAbellas et al. 2017Azzalini et al. 2016Fam et al. 2017Goktekin et al. 2015Kugler et al. 2017Lesiak et al. 2016Mitomo et al. 2016Ojeda et al. 2015Ozel et al. 2016Saad et al. 2016Vaquerizo et al. 2016Wiebe et al. 2015Yamac et al. 2017Age (years)59.2 ± 8.760.0 ± 9.359.40 ± 8.9656.9 ± 9.460.5 ± 7.859.9 ± 8.360.8 ± 11.058 ± 961.9 ± 9.765.3 ± 10.961 ± 1060.4 ± 9.057.8 ± 9.6Male (%)--89.589.590.085.777.589.29885.4758081.886.7Hypertension (%)44.465.469.578.664.38067.85780.578.6--91.380Diabetes (%)22.234.033.321.414.330403351.226.32034.83.3Smoking (%)77.824.848.635.757.135--834.141.5--47.840Family History (%)--29.621.932.9----------30.8----33.3Hyperlipidemia (%)10069.972.452.971.4--61.56446.350.4--65.256.7Prior CABG (%)--2.62.910056.2--17.12.7----6.7Prior PCI (%)--43.846.717.1--4553.83656.139.3----13.3Prior stroke/TIA (%)02.6--0----30.8----------0CKD (%)--5.5--27.11540.1--0------0LVEF (%)--53.2 ± 10.1--51.7 ± 6.7--50.7 ± 10.257.7 ± 10.854 ± 8--59.8 ± 13.8--55.7 ± 15.550.2 ± 6.4

Across studies, patients were predominantly male and had a mean left ventricle ejection more than 50% while the percentages of patients with diabetes (3.3--51.2%), smoking (8--77.8%) and prior-PCI were variable (13.3--56.1%).

Lesion and procedural details are provided in Table [2](#Tab2){ref-type="table"}. The percentage of lesion with moderate/severe calcification (0--70.5%) and that of lesions with a J-CTO score more or equal than 2 (26--100%) were variable while the percentage of post-dilation was almost similar and more than 69.6% in all the studies with the exception of the study by Saad et al. 2016 (25.7%).Table 2Lesion and procedural characteristicsAbellas et al. 2017Azzalini et al. 2016Fam et al. 2017Goktekin et al. 2015Kugler et al. 2017Lesiak et al. 2016Mitomo et al. 2016Ojeda et al. 2015Ozel et al. 2016Saad et al. 2016Vaquerizo et al. 2016Wiebe et al. 2015Yamac et al. 2017LAD (%)22.246.441.951.42057.546.24834.141.6--43.534.3LCX (%)019.012.424.36.77.512.3241726.6--8.725.7RCA (%)77.834.644.832.973.335402848.731.74647.840Moderate/Severe calcifications (%)66.745.870.52846.73032.3----03465.222.9J-CTO score ≥ 255.542.5100--605564.64629.2--26----RVD (mm)3.39 ± 0.223.0 ± 0.42.71 ± 0.55--3.24 ± 0.462.48 ± 0.332.97 ± 0.363.03 ± 0.42.8 ± 0.253.1 ± 0.52.48 ± 0.48--3.02 ± 0.39Mean number of BRS implanted3.222.2 ± 1.12.44 ± 1.122.01 ± 1.03.2 ± 1.31.6 (1--4)1.8 ± 0.72.6 ± 1.91.271.63--2.8 ± 1.02.3 ± 0.9Mean BRS diameter (mm)3.29 ± 0.313.2 ± 0.43.00 ± 0.313.0 ± 0.4--2.90 ± 0.323.0 ± 0.43.030 ± 382.8 ± 0.293.1 ± 0.4--3.1 ± 0.23.2 ± 0.4Total BRS length (mm)21.93 ± 6.4551.3 ± 24.159.75 ± 25.8536.5 ± 19.581.7 ± 29.142.4 ± 21.547.6 ± 19.943 ± 2125.6 ± 4.226 ± 14.753 ± 2364.8 ± 24.258.3 ± 23.3Post-dilation (%)88.990.889.51001009510010097.525.76369.6100Mean post-dilation Balloon diameter (mm)3.45 ± 0.283.3 ± 0.43.35 ± 0.443.5 ± 0.43.3 ± 0.43.15 ± 0.353.3 ± 0.3----------3.4 ± 0.4

Meta-analysis {#Sec11}
-------------

The primary analysis on the composite endpoint of TLR both at short- (\< 6 months) and mid to long- (\> 11 months) term follow-up including all results of the studies is presented in Fig. [2](#Fig2){ref-type="fig"}. At short-term, the summary estimate rate of TLR was 2.6% (95% CI: 1 to 4%, I^2^ = 0%, *P* = 0.887, Fig. [2](#Fig2){ref-type="fig"}a) while at mid to long-term was 3.8% (95% CI: 2 to 6%, I^2^ = 0%, *P* = 0.803, Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2Random effects meta-analysis of target lesion revascularization (TLR) at short-term (panel **a**) and mid to long-term (panel **b**) follow-up. (panel **c**) Random effects meta-analyses of cardiac death, target vessel revascularization, scaffold thrombosis and restenosis at mid to long-term follow-up

Secondary endpoints are reported in Fig. [2](#Fig2){ref-type="fig"}c. At mid to long-term follow-up, the summary estimate rate of cardiac death was 1.1% (95% CI: 0 to 2%, I^2^ = 0%, P = 0.887, Fig. [2](#Fig2){ref-type="fig"}c, first row). The summary estimate rates of scaffold thrombosis and clinical restenosis were respectively 0.9% (95% CI: 0 to 2%, I^2^ = 0%, *P* = 0.919, Fig. [2](#Fig2){ref-type="fig"}c, second row) and 1.8% (95% CI: 0 to 4%, I^2^ = 0%, *P* = 0.448, Fig. [2](#Fig2){ref-type="fig"}c, third row). Finally, the summary estimate rate of target vessel revascularization was 6.6% (95% CI: 0 to 11%, I^2^ = 0%, *P* = 0.04, Fig. [2](#Fig2){ref-type="fig"}c, fourth row).

Meta-regression analysis {#Sec12}
------------------------

Given the differences between Japan-Chronic Total Occlusion (J-CTO) score between the studies, we used the percentage of interventional procedures with J-CTO ≥ 2 in every single study as a moderator in a meta-regression analysis with the effect size of all endpoints evaluated. Probably due to small sample size, we found only no significant interactions across the studies between J-CTO score ≥ 2 on the incidence of TLR (*p* = 0.21), ISR (*p* = 0.11), ScT (*p* = 0.935). Results of meta-regression analyses are displayed in Additional file [1](#MOESM1){ref-type="media"}.

Discussion {#Sec13}
==========

Although the studies leading to their CE marking were mostly based on the analysis of outcomes after treatment of simple lesions, BRS have been used since their introduction in increasingly complex ones. In these settings, including thrombotic, ostial or bifurcation lesions or chronic total occlusions, the potential benefits of vascular resorption could theoretically be larger; on the other side, particularly in light of recent meta-analyses reporting inferior results as compared to modern drug eluting stents in simple lesions \[[@CR26], [@CR27]\], this use is not based on evidence and outcomes remain to be reported.

In this study, we summarize the clinical evidence on the use of BRS for the treatment of CTOs. Our reported TLR rate of 3.8% (FU \> 11 months) compares favorably with that recently reported by Stone et al. (BRS 2.7%, EES 2.3% at 1 year) in a recent meta-analysis of studies on the use of BRS in simple coronary lesions \[[@CR28]\]. As well, the rates of TVR (6.6%), cardiac death (1.1%), scaffold thrombosis (0.9%), clinical scaffold restenosis (1.8%) at mid to long-term follow-up are in line with data reported in previous meta-analyses on the use of DES in CTO lesions. For instance, Yang SS et al. in a meta-analysis of 29 studies \[[@CR29]\] reported an incidence of 1.35% of DES thrombosis in this setting at 1-year follow-up, while Colmenarez et al. reported, in another meta-analysis, a TVR rate of 11.71% at 6 to 36 months follow-up \[[@CR30]\]. In a recent research letter, Brugaletta et al., suggested the use of ticagrelor in patients undergoing PCI of CTO with the potential to improve vascular function and to reduce TLR and symptoms \[[@CR31]\]. Taken together, the present data appear to support the use of BRS in CTO setting.

Limitations {#Sec14}
-----------

First, studies with BRS implantation in CTOs are limited in number and mostly single arm, observational and/or include a small sample size. Second, publication bias may have affected the findings of our meta-analysis of published reports. The lack of routine follow-up angiography in most of the studies does not allow detection of the occurrence of some outcomes like restenosis \[[@CR32]\]. Third, although we explored the effect of covariates on the effect size, the results of the meta-regression should be carefully interpreted in view of the use of study-level covariates and overall low statistical power \[[@CR33]--[@CR35]\]. Fourth, no data are available on procedural success rates. BRS are bulkier and require a more accurate lesion preparation, which is often harder to achieve in complex lesions \[[@CR36]--[@CR41]\]. Finally, the present data reflect outcomes of BRS in selected centers with expertise in this specific setting, and any assumption of safety should be taken with caution.

Conclusions {#Sec15}
===========

Implantation of BRS in a population with CTO is feasible, although further longer-term outcome studies are necessary.

Additional file
===============

 {#Sec16}

Additional file 1:Metaregression analyses - The effect of study-level covariates on the rate of TLR, ScR and ScT. (PPTX 161 kb)

BRS

:   Bioresorbable scaffolds

CABG

:   Coronary artery bypass grafting

CTO

:   Chronic total occlusions

DES

:   Drug-eluting stents

MACE

:   Major adverse cardiovascular events

MI

:   Myocardial infarction

PCI

:   Percutaneous coronary interventions

ScR

:   Scaffold restenosis

ScT

:   Scaffold thrombosis

TLR

:   Target-lesion revascularization

TVF

:   Target vessel failure

TVR

:   Target-vessel revascularization

None

Funding {#FPar1}
=======

None

Availability of data and materials {#FPar2}
==================================

All data generated or analysed during this study are included in this published article.

AP, SDR, and TG designed the study and acquired, analysed, and interpreted data. AP, MG and RA did the literature search and study selection procedures. TM and CI drafted the manuscript, with critical revisions for important intellectual content from all authors. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable

Consent for publication {#FPar4}
=======================

Not applicable

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
